Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Accumulating evidence suggests a link between non-alcoholic fatty liver disease (NAFLD) and brain health. However, population-based evidence on the association between NAFLD and dementia remains unclear. This study was conducted to determine the association between NAFLD and incident dementia. Methods: The study population included 608,994 adults aged ≥60 years who underwent health examinations between 2009 and 2010. Data were collected from the Korean National Health Insurance Service database. NAFLD was assessed using the fatty liver index (FLI). A Cox proportional hazards regression model was used to determine the association between NAFLD and dementia. Results: During the 6,495,352 person-years of follow-up, 48,538 participants (8.0%) developed incident dementia. The participants were classified into low (FLI <30), intermediate (FLI ≥30 and <60), and high (FLI ≥60) groups. In the overall study population, the FLI groups were associated with a risk of dementia (P for trend <0.001). After propensity score matching, a low FLI was associated with a reduced risk of dementia (adjusted hazard ration [aHR], 0.96; 95% confidence interval [CI], 0.93–0.98; P=0.002), whereas a high FLI (NAFLD) was associated with an increased risk of dementia (aHR, 1.05; 95% CI, 1.02–1.08; P=0.001). A higher risk of dementia in the high FLI group than in the intermediate FLI group was attributed to Alzheimer’s disease (aHR, 1.04; 95% CI, 1.01–1.07; P=0.004) rather than vascular dementia (aHR, 0.94; 95% CI, 0.75–1.18; P=0.602). Conclusions: NAFLD was associated with an increased risk of dementia, which was attributed to an increased risk of Alzheimer’s disease.
Abstract
Background/Aims: Accumulating evidence suggests a link between non-alcoholic fatty liver disease (NAFLD) and brain health. However, population-based evidence on the association between NAFLD and dementia remains unclear. This study was conducted to determine the association between NAFLD and incident dementia. Methods: The study population included 608,994 adults aged ≥60 years who underwent health examinations between 2009 and 2010. Data were collected from the Korean National Health Insurance Service database. NAFLD was assessed using the fatty liver index (FLI). A Cox proportional hazards regression model was used to determine the association between NAFLD and dementia. Results: During the 6,495,352 person-years of follow-up, 48,538 participants (8.0%) developed incident dementia. The participants were classified into low (FLI <30), intermediate (FLI ≥30 and <60), and high (FLI ≥60) groups. In the overall study population, the FLI groups were associated with a risk of dementia (P for trend <0.001). After propensity score matching, a low FLI was associated with a reduced risk of dementia (adjusted hazard ration [aHR], 0.96; 95% confidence interval [CI], 0.93–0.98; P=0.002), whereas a high FLI (NAFLD) was associated with an increased risk of dementia (aHR, 1.05; 95% CI, 1.02–1.08; P=0.001). A higher risk of dementia in the high FLI group than in the intermediate FLI group was attributed to Alzheimer’s disease (aHR, 1.04; 95% CI, 1.01–1.07; P=0.004) rather than vascular dementia (aHR, 0.94; 95% CI, 0.75–1.18; P=0.602). Conclusions: NAFLD was associated with an increased risk of dementia, which was attributed to an increased risk of Alzheimer’s disease.
참고문헌 (40)
- Wu YT, "The changing prevalence and incidence of dementia over time-current evidence", Nat Rev Neurol, 13, pp.327~339 (2017)
- Etters L, "Caregiver burden among dementia patient caregivers : a review of the literature", J Am Acad Nurse Pract, 20, pp.423~428 (2008)
- GBD 2016 Dementia Collaborators, "Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016 : a systematic analysis for the Global Burden of Disease Study 2016", Lancet Neurol, 18, pp.88~106 (2019)
- Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
- Satizabal CL, "Incidence of dementia over three decades in the Framingham heart study", N Engl J Med, 374, pp.523~532 (2016)
- Elwood P, "Healthy lifestyles reduce the incidence of chronic diseases and dementia : evidence from the Caerphilly cohort study", PLoS One, 8, pp.e81877~ (2013)
- Bertolotti M, "Nonalcoholic fatty liver disease and aging : epidemiology to management", World J Gastroenterol, 20, pp.14185~14204 (2014)
- Baumgart M, "Summary of the evidence on modifiable risk factors for cognitive decline and dementia : a population-based perspective", Alzheimers Dement, 11, pp.718~726 (2015)
- Seo SW, "Nonalcoholic fatty liver disease is associated with cognitive function in adults", Neurology, 86, pp.1136~1142 (2016)
- Solfrizzi V, "Liver fibrosis score, physical frailty, and the risk of dementia in older adults: the Italian longitudinal study on aging", Alzheimers Dement(N Y), 6, pp.e12065~ (2020)
- Shang Y, "Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction", JHEP Rep, 3, pp.100218~ (2020)
- Weinstein G, "Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults : the Framingham study", Liver Int, 39, pp.1713~1721 (2019)
- Labenz C, "Incident dementia in elderly patients with nonalcoholic fatty liver disease in Germany", Dig Dis Sci, 66, pp.3179~3185 (2021)
- Seong SC, "Data resource profile : the national health information database of the national health insurance service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
- Bedogni G, "The fatty liver index : a simple and accurate predictor of hepatic steatosis in the general population", BMC Gastroenterol, 6, pp.33~ (2006)
- European Association for the Study of the Liver(EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
- Lee YH, "Nonlaboratory-based self-assessment screening score for nonalcoholic fatty liver disease : development, validation and comparison with other scores", PLoS One, 9, pp.e107584~ (2014)
- Huang PL, "A comprehensive definition for metabolic syndrome", Dis Model Mech, 2, pp.231~237 (2009)
- Sundararajan V, "New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality", J Clin Epidemiol, 57, pp.1288~1294 (2004)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Weinstein G, "Association of nonalcoholic fatty liver disease with lower brain volume in healthy middle-aged adults in the Framingham study", JAMA Neurol, 75, pp.97~104 (2018)
- de la Monte SM, "Brain metabolic dysfunction at the core of Alzheimer’s disease", Biochem Pharmacol, 88, pp.548~559 (2014)
- de la Monte SM, "Insulin resistance and neurodegeneration : progress towards the development of new therapeutics for Alzheimer’s disease", Drugs, 77, pp.47~65 (2017)
- Kim DG, "Non-alcoholic fatty liver disease induces signs of Alzheimer’s disease(AD)in wild-type mice and accelerates pathological signs of AD in an AD model", J Neuroinflammation, 13, pp.1~ (2016)
- Karbalaei R, "Protein-protein interaction analysis of Alzheimer`s disease and NAFLD based on systems biology methods unhide common ancestor pathways", Gastroenterol Hepatol Bed Bench, 11, pp.27~33 (2018)
- Kanekiyo T, "The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer’s disease", Front Aging Neurosci, 6, pp.93~ (2014)
- Tamaki C, "Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide(1 40)by intracellular translocation of low-density lipoprotein receptor-related protein 1(LRP-1)to the plasma membrane in hepatocytes", Mol Pharmacol, 72, pp.850~855 (2007)
- Sehgal N, "Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver", Proc Natl Acad Sci U S A, 109, pp.3510~3515 (2012)
- RansohoffRM, "How neuroinflammation contributes to neurodegeneration", Science, 353, pp.777~783 (2016)
- Ye D, "Lipocalin-2mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2", J Hepatol, 65, pp.988~997 (2016)
- Mondal A, "Lipocalin 2 induces neuroinflammation and blood-brain barrier dysfunction through liver-brain axis in murine model of nonalcoholic steatohepatitis", J Neuroinflammation, 17, pp.201~ (2020)
- Lindestam Arlehamn CS, "Roles for the adaptive immune system in Parkinson’s and Alzheimer’s diseases", Curr Opin Immunol, 59, pp.115~120 (2019)
- Gate D, "Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease", Nature, 577, pp.399~404 (2020)
- Grohmann M, "Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC", Cell, 175, pp.1289~1306 (2018)
- Ghazarian M, "Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome", Sci Immunol (2017)
- Wolf MJ, "Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes", Cancer Cell, 26, pp.549~564 (2014)
- Bhattacharjee J, "Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis", Hepatol Commun, 1, pp.299~310 (2017)
- Weinstein G, "Author response : non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults : the Framingham study", Liver Int, 40, pp.1240~ (2020)
- Weinstein G, "Clinical and environmental correlates of serum BDNF : a descriptive study with plausible implications for AD research", Curr Alzheimer Res, 14, pp.722~730 (2017)
- Calabrese F, "Brain-derived neurotrophic factor : a bridge between inflammation and neuroplasticity", Front Cell Neurosci, 8, pp.430~ (2014)